Meeting
2022 ASCO Annual Meeting
NEBULA: A multicenter phase 1a/b study of a tumor-selective transgene-expressing adenoviral vector, NG-641, and nivolumab in patients with metastatic or advanced epithelial tumors.
Authors
Thomas Lillie
PsiOxus Therapeutics Ltd, Abingdon, United Kingdom
Thomas Lillie , Eileen E. Parkes , Christian Ottensmeier , David Krige , Behnaz Ravanfar , Vladimir Evilevitch , Matthew Thomas , Lee S. Rosen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
New Targets and New Technologies (IO)
Clinical Trial Registration Number
NCT05043714
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS2682)
DOI
10.1200/JCO.2022.40.16_suppl.TPS2682
Abstract #
TPS2682
Poster Bd #
330a
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Integrated biomarker study of neoadjuvant pepinemab and nivolumab in patients with resectable metastatic melanoma.
First Author: Michael C. Lowe
Poster
2023 ASCO Annual Meeting
ENVASARC: A pivotal trial of envafolimab and envafolimab in combination with ipilimumab in patients with advanced or metastatic undifferentiated pleomorphic sarcoma or myxofibrosarcoma who have progressed on prior chemotherapy.
First Author: Richard F. Riedel
Poster
2023 ASCO Genitourinary Cancers Symposium
Association of liver metastases, tumor microenvironment, and treatment outcomes in patients with urothelial bladder cancer treated with tislelizumab.
First Author: Linlin Xu
Poster
2023 ASCO Gastrointestinal Cancers Symposium
LAG3-related factors to predict response to nivolumab monotherapy in advanced gastric cancer (WJOG10417GTR study).
First Author: Kai Tsugaru